The topline results, which were pre-announced earlier this month, were driven by growth in NGS and clinical services revenue.
NeoGenomics Raises Full-Year 2026 Guidance on 11 Percent Q3 Revenue Growth
NeoGenomics Raises Full-Year 2026 Guidance on 11 Percent Q3 Revenue Growth
ebx.sh
October 29, 2026 at 5:45 PM
The topline results, which were pre-announced earlier this month, were driven by growth in NGS and clinical services revenue.
#NEO NeoGenomics Reports Third Quarter 2026 Results
https://www.stocktitan.net/news/NEO/neo-genomics-reports-third-quarter-2026-2ct48dgrknhl.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NEO/neo-genomics-reports-third-quarter-2026-2ct48dgrknhl.html?utm_source=stocktitan-bluesky&utm_medium=social
NeoGenomics Reports Third Quarter 2026 Results
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 28, 2026 at 8:05 PM
#NEO NeoGenomics Reports Third Quarter 2026 Results
https://www.stocktitan.net/news/NEO/neo-genomics-reports-third-quarter-2026-2ct48dgrknhl.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NEO/neo-genomics-reports-third-quarter-2026-2ct48dgrknhl.html?utm_source=stocktitan-bluesky&utm_medium=social
📈 KLA forecasts $4.7B December-quarter revenue.
📈 NeoGenomics raised 2026 guidance to $807M-$809M.
📈 Impinj anticipates Q4 revenue of $104M-$107M.
📈 Alkami projects $530.5M-$532M 2026 revenue.
📈 NeoGenomics raised 2026 guidance to $807M-$809M.
📈 Impinj anticipates Q4 revenue of $104M-$107M.
📈 Alkami projects $530.5M-$532M 2026 revenue.
October 29, 2026 at 5:37 AM
📈 KLA forecasts $4.7B December-quarter revenue.
📈 NeoGenomics raised 2026 guidance to $807M-$809M.
📈 Impinj anticipates Q4 revenue of $104M-$107M.
📈 Alkami projects $530.5M-$532M 2026 revenue.
📈 NeoGenomics raised 2026 guidance to $807M-$809M.
📈 Impinj anticipates Q4 revenue of $104M-$107M.
📈 Alkami projects $530.5M-$532M 2026 revenue.
🚨 $NEO
On October 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
On October 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
SEC Filing: NEO
Click to view the official SEC document.
www.sec.gov
October 28, 2026 at 8:09 PM
🚨 $NEO
On October 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
On October 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
People in the news for the week of Oct. 5, 2026: Diana Bianchi, Erik Zmuda, Catherine Doherty: John Brottem, Amelia Merrill, Warren Stone, Tony Zook, Lynn Tetrault, Michael Kelly
People in the News at CHOP, 3billion, Quest Diagnostics, Alamar Biosciences, NeoGenomics
People in the News at CHOP, 3billion, Quest Diagnostics, Alamar Biosciences, NeoGenomics
ebx.sh
October 10, 2026 at 2:13 AM
People in the news for the week of Oct. 5, 2026: Diana Bianchi, Erik Zmuda, Catherine Doherty: John Brottem, Amelia Merrill, Warren Stone, Tony Zook, Lynn Tetrault, Michael Kelly
NeoGenomics (#$NEO) fell 12%+ Tuesday after naming COO Warren Stone CEO and previewing Q3. Preliminary revenue of ~$209M beat the $206M consensus, but shares were up 86%+ YoY, so expectations were high.
prismmarketview.com/companies/ne...
prismmarketview.com/companies/ne...
NeoGenomics, Inc.
Based in Fort Myers, Florida, NeoGenomics, Inc. (NASDAQ: NEO) operates a specialized network of cancer-focused testing laboratories across the United States and
prismmarketview.com
October 7, 2026 at 12:08 PM
NeoGenomics (#$NEO) fell 12%+ Tuesday after naming COO Warren Stone CEO and previewing Q3. Preliminary revenue of ~$209M beat the $206M consensus, but shares were up 86%+ YoY, so expectations were high.
prismmarketview.com/companies/ne...
prismmarketview.com/companies/ne...
The company reported preliminary Q3 2026 revenue of roughly $209 million and said it has appointed its current President and COO as CEO, effective Jan. 4, 2027.
NeoGenomics Projects 11 Percent Jump in Q3 Revenue, Announces New CEO
NeoGenomics Projects 11 Percent Jump in Q3 Revenue, Announces New CEO
ebx.sh
October 6, 2026 at 7:29 PM
The company reported preliminary Q3 2026 revenue of roughly $209 million and said it has appointed its current President and COO as CEO, effective Jan. 4, 2027.
Investing News - Disclosures from Edgar & Edgarette
$NEO Neogenomics · FY revenue $727M · formerly American Communications Enterprises
📜 Somebody edited the fine print. I read all of it, obviously.
SEC Item 5.03 · filed 5 Oct
the filing · the board
$NEO Neogenomics · FY revenue $727M · formerly American Communications Enterprises
📜 Somebody edited the fine print. I read all of it, obviously.
SEC Item 5.03 · filed 5 Oct
the filing · the board
October 6, 2026 at 8:31 PM
Investing News - Disclosures from Edgar & Edgarette
$NEO Neogenomics · FY revenue $727M · formerly American Communications Enterprises
📜 Somebody edited the fine print. I read all of it, obviously.
SEC Item 5.03 · filed 5 Oct
the filing · the board
$NEO Neogenomics · FY revenue $727M · formerly American Communications Enterprises
📜 Somebody edited the fine print. I read all of it, obviously.
SEC Item 5.03 · filed 5 Oct
the filing · the board
{Edgarette} 🔖 $NEO NeoGenomics · FY2025
Revenue $727M, debt $342M. Operating margin -15.9%, was -13.9%.
Peers (Services-Testing…, 8): 14.9%.
My 80% range: $698M–$901M next year. Logged in advance · receipt #2c628c.
Margin slipped. Noted, not judged. 🔖
the card
Revenue $727M, debt $342M. Operating margin -15.9%, was -13.9%.
Peers (Services-Testing…, 8): 14.9%.
My 80% range: $698M–$901M next year. Logged in advance · receipt #2c628c.
Margin slipped. Noted, not judged. 🔖
the card
October 6, 2026 at 8:31 PM
{Edgarette} 🔖 $NEO NeoGenomics · FY2025
Revenue $727M, debt $342M. Operating margin -15.9%, was -13.9%.
Peers (Services-Testing…, 8): 14.9%.
My 80% range: $698M–$901M next year. Logged in advance · receipt #2c628c.
Margin slipped. Noted, not judged. 🔖
the card
Revenue $727M, debt $342M. Operating margin -15.9%, was -13.9%.
Peers (Services-Testing…, 8): 14.9%.
My 80% range: $698M–$901M next year. Logged in advance · receipt #2c628c.
Margin slipped. Noted, not judged. 🔖
the card
Constellation Energy shares surged after Google signed a massive long-term power contract with the company. Option Care Health soared on reports of buyout talks, with McKesson and private equity jointly pursuing the acquisition. Berkshire Hathaway revealed a stake in Lennar. NeoGenomics...
October 6, 2026 at 2:49 PM
Constellation Energy shares surged after Google signed a massive long-term power contract with the company. Option Care Health soared on reports of buyout talks, with McKesson and private equity jointly pursuing the acquisition. Berkshire Hathaway revealed a stake in Lennar. NeoGenomics...
[Breaking] Shock of AI Power Deal! Why Constellation Energy Shares Surged
▼Read More
https://biz-matome.com/archives/60526
▼Read More
https://biz-matome.com/archives/60526
[Breaking] Shock of AI Power Deal! Why Constellation Energy Shares Surged - AIビジネスまとめ
Constellation Energy shares surged after Google signed a massive long-term power contract with the company. Option Care Health soared on reports of buyout talks, with McKesson and private equity jointly pursuing the acquisition. Berkshire Hathaway revealed a stake in Lennar. NeoGenomics gained after announcing a leadership succession plan and strong Q3 sales. Advanced Micro Devices rose as a financial institution raised its price target, driven by expected AI-related demand for processors. Procter & Gamble and Corteva also climbed following rating upgrades.
biz-matome.com
October 6, 2026 at 2:49 PM
[Breaking] Shock of AI Power Deal! Why Constellation Energy Shares Surged
▼Read More
https://biz-matome.com/archives/60526
▼Read More
https://biz-matome.com/archives/60526
NeoGenomics Signals Full-Year Guidance Hike on 28% NGS Growth, Announces CEO Transition https://signalbloom.ai/news/NEO/neogenomics-signals-full-year-guidance-hike-on-28-ngs-growth-announces-ceo-transition $NEO #Earnings via @signalbloom.ai
October 5, 2026 at 8:11 PM
NeoGenomics Signals Full-Year Guidance Hike on 28% NGS Growth, Announces CEO Transition https://signalbloom.ai/news/NEO/neogenomics-signals-full-year-guidance-hike-on-28-ngs-growth-announces-ceo-transition $NEO #Earnings via @signalbloom.ai
#NEO NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
https://www.stocktitan.net/news/NEO/neo-genomics-announces-executive-leadership-and-board-of-directors-gyqjsjl33dz3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NEO/neo-genomics-announces-executive-leadership-and-board-of-directors-gyqjsjl33dz3.html?utm_source=stocktitan-bluesky&utm_medium=social
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 5, 2026 at 8:05 PM
#NEO NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
https://www.stocktitan.net/news/NEO/neo-genomics-announces-executive-leadership-and-board-of-directors-gyqjsjl33dz3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NEO/neo-genomics-announces-executive-leadership-and-board-of-directors-gyqjsjl33dz3.html?utm_source=stocktitan-bluesky&utm_medium=social
#$NEO NeoGenomics names Warren Stone as CEO effective Jan. 4
- Stone promoted from President & COO
- Tony Zook transitions to Executive Chair
- Internal succession — no outside search
- Stone promoted from President & COO
- Tony Zook transitions to Executive Chair
- Internal succession — no outside search
October 5, 2026 at 8:14 PM
#$NEO NeoGenomics names Warren Stone as CEO effective Jan. 4
- Stone promoted from President & COO
- Tony Zook transitions to Executive Chair
- Internal succession — no outside search
- Stone promoted from President & COO
- Tony Zook transitions to Executive Chair
- Internal succession — no outside search
🚨 $NEO
On October 5, 2026, NeoGenomics, Inc. issued a press release that included certain preliminary financial results as of and for the quarter ended September 30, 2026. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by refe...
On October 5, 2026, NeoGenomics, Inc. issued a press release that included certain preliminary financial results as of and for the quarter ended September 30, 2026. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by refe...
SEC Filing: NEO
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 8:31 PM
🚨 $NEO
On October 5, 2026, NeoGenomics, Inc. issued a press release that included certain preliminary financial results as of and for the quarter ended September 30, 2026. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by refe...
On October 5, 2026, NeoGenomics, Inc. issued a press release that included certain preliminary financial results as of and for the quarter ended September 30, 2026. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by refe...